Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalic Acid SCHEMBL8811649 | 0.98 | TSHR (0.70) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL63466 | 0.98 | TSHR (0.70) | TSHRCA1CA2CA12CA7 | |
| Terephthalic Acid SCHEMBL18394717 | 0.98 | TSHR (0.70) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL27555709 | 0.98 | TSHR (0.70) | TSHRCA1CA2CA12CA7 | |
| Terephthalic Acid SCHEMBL4349174 | 0.98 | TSHR (0.70) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL2395112 | 0.95 | TSHR (0.67) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL11668494 | 0.95 | TSHR (0.67) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL27860895 | 0.95 | TSHR (0.67) | TSHRCA1CA2CA12CA7 | |
| Methyl Alcohol SCHEMBL29033870 | 0.95 | TSHR (0.67) | TSHRCA1CA2CA12CA7 | |
| Terephthalic Acid SCHEMBL27555710 | 0.95 | TSHR (0.67) | TSHRCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0125195-B1 | 4'-FLAVONECARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | CORTIAL S.A. (FR) | 1987-09-30 | — | — | EP | claimed |
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-10-10 | — | — | US | disclosed |
| EP-3478661-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018002847-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-01-04 | — | — | WO | disclosed |
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| WO-2016086071-A1 | SPECTRALLY ENCODED CONSUMABLE SPECTROMETER APPARATUS AND METHODS | NUEOU, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9312043-B2 | Polyamide composition containing electrically conductive carbon | EVONIK DEGUSSA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| US-9150922-B2 | Cyanine compounds and their application as quenching compounds | Life Technologies Corporation (US) | 2015-10-06 | — | — | US | disclosed |
| US-4600788-A | ANTIDIABETIC AGENTS, DIURETICS/ ALYST, ENAMINE | SOCIETE CORTIAL, S.A. (FR) | 1986-07-15 | — | — | US | disclosed |
| US-4600788-A | ANTIDIABETIC AGENTS, DIURETICS/ ALYST, ENAMINE | SOCIETE CORTIAL, S.A. (FR) | 1986-07-15 | — | — | US | disclosed |
| US-4339455-A | 1-(3-Pyridyl)-2,2,2-trihaloethyl compounds and fungicidal compositions containing the same | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1982-07-13 | — | — | US | disclosed |
| US-4189486-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4137399-A | Method of preparing functionalized celluloses | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
| US-4118232-A | Photographic material containing sulphonic acid group containing disazo dyestuffs | CIBA-GEIGY AG (CH) | 1978-10-03 | — | — | US | disclosed |
| US-4086209-A | Novel nitrogen-containing aromatic polymers and process for their preparation | TEIJIN LIMITED (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4085090-A | Aromatic polymers containing a nitrogen-containing ring group, and process for preparation thereof | TEIJIN LIMITED (JA) | 1978-04-18 | — | — | US | disclosed |
| US-4051123-A | Sulfonic-acid-group containing disazo dyestuffs | CIBA-GEIGY AG (CH) | 1977-09-27 | — | — | US | disclosed |
| US-4002600-A | OR ISOPHTHALIC CID, A PROCESS FOR THEIR MANUFACTURE AND THEIR USEAMIDEOPHTHALIC ACID, A POROCESS FOR THE GROUPS | CIBA-GEIGY CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CYP51A1, TYMP, TYMS | CA2 4838/4885TSHR 4673/4885CA1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.